Epidemiology of treatment resistant depression among major depressive disorder patients in Israel

Moser, Sarah Sharman; Chodick, Gabriel; Gelerstein, Shulamit; David, Nava Barit Ben; Shalev, Varda; Stein-Reisner, Orit

doi:10.1186/s12888-022-04184-8

Cited by 14 publications

(8 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…47 Although PD is among the most common comorbid psychiatric conditions in TRD, none of these studies reported on participants with both TRD and PD. [48][49][50] Our study supports previous studies showing that a pharmacotherapy including quetiapine can improve subjective sleep in TRD independently of the presence of PD or not. However, we found a greater improvement of sleep quality in TRD/PD+ compared with TRD/PD− treated with a pharmacotherapy, which included quetiapine.…”

Section: Discussionsupporting

confidence: 89%

“…In a 20-week open trial with quetiapine (315 ± 109 mg, flexible dose), 14 patients with TRD showed a decrease of more than 4 points on the TSS at their first time of measurement (eg, after only 2 weeks of treatment) 47 . Although PD is among the most common comorbid psychiatric conditions in TRD, none of these studies reported on participants with both TRD and PD 48–50 . Our study supports previous studies showing that a pharmacotherapy including quetiapine can improve subjective sleep in TRD independently of the presence of PD or not.…”

Section: Discussionsupporting

confidence: 85%

See 1 more Smart Citation

Sleep Quality After Quetiapine Augmentation in Patients With Treatment-Resistant Depression and Personality Disorders

Moderie,

King,

Nuñez

et al. 2023

J Clin Psychopharmacol

View full text Add to dashboard Cite

Purpose/Background Quetiapine is a first-line augmenting agent for treatment-resistant depression (TRD) and is used off-label in insomnia. Quetiapine and its active metabolite norquetiapine act mostly on 5-HT2A, 5-HT2C, H1, and D2 as antagonists and on 5-HT1A as partial agonists. Patients with TRD often have comorbid personality disorder (PD), and evidence suggests an association between sleep disturbance and recovery among patients with PD. Here, we aimed to evaluate the effects of quetiapine on sleep in TRD patients with and without PD (PD+/PD−). Methods/Procedures We reviewed health records of 38 patients with TRD (20 TRD/PD+) who had been treated with a pharmacotherapy regimen including quetiapine. Clinical outcomes were determined by comparing changes in sleep items of the Hamilton Depression Rating Scale at the beginning (T0) and after 3 months of an unchanged treatment (T3). Findings/Results Patients with TRD/PD+ and TRD/PD− taking quetiapine showed significant improvement in sleep items from T0 to T3 (P < 0.001, η p 2 ≥ 0.19). There was a significant personality × time interaction for sleep-maintenance insomnia (P = 0.006, η p 2 = 0.23), with TRD/PD+ showing a greater improvement at T3 compared with TRD/PD− (P = 0.01). While exploring other sleep items, no personality × time interaction was found. In the TRD/PD− group, improvement in sleep items was associated with an overall improvement in depressive symptoms (r = 0.55, P = 0.02). Implications/Conclusions Quetiapine induced greater improvements in sleep-maintenance insomnia among TRD/PD+ patients than TRD/PD−. These findings suggest quetiapine could have a therapeutic role for insomnia in PD underscoring a distinct underlying neurobiological mechanism of sleep disturbance in people living with PD.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 85%

Sleep Quality After Quetiapine Augmentation in Patients With Treatment-Resistant Depression and Personality Disorders

Moderie,

King,

Nuñez

et al. 2023

J Clin Psychopharmacol

View full text Add to dashboard Cite

show abstract

“…A similar French research detected 25.8 people suffering from TRD per 10,000 patients ( 41 ). Furthermore, TRD proportion was estimated to be 4.2% in Italy ( 42 ), 24.4% in Israel ( 43 ) and 19.6% in Thailand ( 44 ). Although prevalence data are heterogeneous, the common element is that TRD is quite frequent in ordinary clinical practice.…”

Section: Results From the Narrative Clinical Reviewmentioning

confidence: 99%

Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review

Di Vincenzo,

Martiadis,

Della Rocca

et al. 2024

Front. Psychiatry

View full text Add to dashboard Cite

Introduction and aimsTreatment-resistant depression (TRD) occurs when at least two different antidepressants, taken at the right dosage, for adequate period of time and with continuity, fail to give positive clinical effects. Esketamine, the S-enantiomer of ketamine, was recently approved for TRD treatment from U.S. Food and Drug Administration and European Medicine Agency. Despite proved clinical efficacy, many misconceptions by clinicians and patients accompany this medication. We aimed to review the most common “false myths” regarding TRD and esketemine, counterarguing with evidence-based facts.MethodsThe keywords “esketamine”, “treatment resistance depression”, “depression”, “myth”, “mythology”, “pharmacological treatment”, and “misunderstanding” were entered in the main databases and combined through Boolean operators.ResultsMisconceptions regarding the TRD prevalence, clinical features and predictors have been found. With respect of esketamine, criteria to start treatment, dissociative symptoms, potential addiction and aspects of administration and monitoring, were found to be affected by false beliefs by clinicians and patients.Discussion and conclusionTRD represents a challenging condition, requiring precise diagnosis in order to achieve patient’s full recovery. Esketamine has been proved as an effective medication to treat TRD, although it requires precautions. Evidence can inform clinical practice, in order to offer this innovative treatment to all patients with TRD.

show abstract

“…Differences in the definition of TRD have resulted in highly variable estimates of its prevalence rate 99 . TRD is often stated to affect approximately 30% of persons receiving antidepressant treatment in research settings, while its prevalence in real world practice is estimated to range between 6 and 55% 32,98‐101 .…”

Section: Prevalence Of Treatment‐resistant Depressionmentioning

confidence: 99%

Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions

McIntyre,

Alsuwaidan,

Baune

et al. 2023

World Psychiatry

180

View full text Add to dashboard Cite

Treatment‐resistant depression (TRD) is common and associated with multiple serious public health implications. A consensus definition of TRD with demonstrated predictive utility in terms of clinical decision‐making and health outcomes does not currently exist. Instead, a plethora of definitions have been proposed, which vary significantly in their conceptual framework. The absence of a consensus definition hampers precise estimates of the prevalence of TRD, and also belies efforts to identify risk factors, prevention opportunities, and effective interventions. In addition, it results in heterogeneity in clinical practice decision‐making, adversely affecting quality of care. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have adopted the most used definition of TRD (i.e., inadequate response to a minimum of two antidepressants despite adequacy of the treatment trial and adherence to treatment). It is currently estimated that at least 30% of persons with depression meet this definition. A significant percentage of persons with TRD are actually pseudo‐resistant (e.g., due to inadequacy of treatment trials or non‐adherence to treatment). Although multiple sociodemographic, clinical, treatment and contextual factors are known to negatively moderate response in persons with depression, very few factors are regarded as predictive of non‐response across multiple modalities of treatment. Intravenous ketamine and intranasal esketamine (co‐administered with an antidepressant) are established as efficacious in the management of TRD. Some second‐generation antipsychotics (e.g., aripiprazole, brexpiprazole, cariprazine, quetiapine XR) are proven effective as adjunctive treatments to antidepressants in partial responders, but only the olanzapine‐fluoxetine combination has been studied in FDA‐defined TRD. Repetitive transcranial magnetic stimulation (TMS) is established as effective and FDA‐approved for individuals with TRD, with accelerated theta‐burst TMS also recently showing efficacy. Electroconvulsive therapy is regarded as an effective acute and maintenance intervention in TRD, with preliminary evidence suggesting non‐inferiority to acute intravenous ketamine. Evidence for extending antidepressant trial, medication switching and combining antidepressants is mixed. Manual‐based psychotherapies are not established as efficacious on their own in TRD, but offer significant symptomatic relief when added to conventional antidepressants. Digital therapeutics are under study and represent a potential future clinical vista in this population.

show abstract

Epidemiology of treatment resistant depression among major depressive disorder patients in Israel

Cited by 14 publications

References 59 publications

Sleep Quality After Quetiapine Augmentation in Patients With Treatment-Resistant Depression and Personality Disorders

Sleep Quality After Quetiapine Augmentation in Patients With Treatment-Resistant Depression and Personality Disorders

Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review

Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions

Contact Info

Product

Resources

About